News

Synovial sarcoma is a rare, aggressive soft tissue cancer with few effective treatment options, which means patients often have a poor prognosis.

A study published in the journal Cell from Hui-Kuan Lin and colleagues could help revive drugs once considered too big to work.

A multi-faceted study from Department of Pharmacology and Cancer Biology researchers shows for the first time that blocking an under-studied enzyme called PKN2 may be the key to stopping aggressive, treatment-resistant cancers.

The Distinguished Neurotoxicologist Award recognizes those "who have made important, high-impact scientific, regulatory, or service contributions" to Neurotoxicology.

The student awardees were selected for their publication record, influence on the research direction of their laboratory, and noteworthy and distinctive contributions to the scientific and academic community.

Research led by Greg Wang, PhD, shows how clusters of cancer cells called NUP98 fusions lead to leukemia. The study was published in the journal in Molecular Cell.

The Duke Department of Pharmacology and Cancer Biology ranks seventh in the nation in NIH funding, based on grants awarded during the federal fiscal year ending September 30, 2024.

The National Institutes of Health's proposal to cap reimbursement of facilities and administrative (F&A) costs on research grants at 15% would significantly slow or cease scientific and biomedical research at Duke and other research institutions. Here is an explanation of what F&A costs are and why they are such a critical piece of the research endeavor.

Dr. Oliver is focused on understanding the biology of under-studied subtypes of lung cancer, specifically squamous and small cell lung cancer. Her lab investigates mechanisms of tumor development, plasticity, and drug resistance to uncover vulnerabilities that can be therapeutically targeted.